Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P010033/S052

QuantiFERON-TB Gold Test and QuantiFERON-TB Gold Plus Test

Qiagen · Decision date Jan 23, 2026

FDA DECISIONP010033/S052

What did the FDA decide?

FDA records P010033/S052 as a supplement to PMA P010033, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jan 23, 2026.

FDA approval order statement

an internal site to internal site transfer of a manufacturing process
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Microbiology
Decision date
Jan 23, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P010033/S052
Regulatory pathway
PMA supplement
Applicant
Qiagen
Product code
NCD
Decision code
OK30
Decision date
Jan 23, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: TEST, IMMUNITY, CELL MEDIATED, MYCOBACTERIUM TUBERCULOSIS.

Applicant
Qiagen
Product code
NCD
FDA device class
3

For the original device and its historical approval scope, see PMA P010033. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P010033 · Original PMA

    QUANTTFERON-TB GOLD AND TB GOLD-IN-THE-TUBE

  2. P010033/S051 · Related supplement

    QuantiFERON-TB Gold Plus Test

  3. P010033/S052 received

    Application receipt date recorded by FDA.

  4. P010033/S052 · FDA decision

    30-Day Notice

  5. P010033/S053 · Related supplement

    QuantiFERON-TB Gold Plus Test

Timeline entries are records held by MedtechLedger for P010033. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P010033

Product / regulatory recordCompanyPathwayDecision dateSource
QiagenPMA approvalNov 28, 2001FDA
QiagenPMA supplementNov 21, 2025FDA
QiagenPMA supplementOct 14, 2026FDA

Explore the linked device profile

Other records with product code NCD

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Qiagen

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
19300 Germantown Rd., Germantown, MD, 20874

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records